Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
GILD Stock News and Mentions of Gilead Sciences, Inc. Stocktwits
Updated: April 27, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Gilead Sciences Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Gilead Sciences, Inc. (GILD).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Gilead Sciences stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Gilead Sciences, Inc. (GILD)
April 27, 2024 (06:18) / "Stocknews.com" (by Defense World Staff)
Gilead Sciences ( NASDAQ:GILD ) Upgraded at StockNews.com
Gilead Sciences ( NASDAQ:GILD - Get Free Report ) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a note issued to investors on Saturday. Other equities analysts also recently issued reports about the company.
In Article Trend: Somewhat-Bullish
April 26, 2024 (19:15) / "Benzinga" (by Benzinga Insights)
Gilead Sciences Unusual Options Activity - Gilead Sciences ( NASDAQ:GILD )
Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
April 26, 2024 (14:24) / "Zacks Commentary" (by Zacks Equity Research)
Gilead ( GILD ) Q1 Loss Narrower Than Expected, Sales Beat
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
In Article Trend: Neutral
April 26, 2024 (11:58) / "Zacks Commentary" (by Zacks Equity Research)
Merus ( MRUS ) Moves 7.1% Higher: Will This Strength Last?
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
In Article Trend: Somewhat-Bullish
April 25, 2024 (21:15) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Reports Q1 Loss, Tops Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of 11.41% and 5.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
April 25, 2024 (20:07) / "Investors Business Daily" (by ALLISON GATLIN)
Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?
Gilead Sciences ( GILD ) beat Wall Street's first-quarter sales forecasts Thursday on the back of its Covid treatment, Veklury, but lighter-than-expected sales of cancer drugs could hamper Gilead stock. Two out of three of Gilead's cancer drugs - cell therapy Tecartus and antibody drug ...
In Article Trend: Neutral
April 25, 2024 (20:03) / "Barrons" (by Josh Nathan-Kazis)
Gilead Beats Earnings Expectations After Rocky Quarter
After a sell off that saw its shares fall nearly 20% this year, the biotech Gilead Sciences turned in first-quarter results on Thursday that were slightly better than anticipated. Sales for the quarter were $6.7 billion, beating the analyst consensus estimate as calculated by FactSet , which was ...
In Article Trend: Neutral
April 25, 2024 (11:54) / "Benzinga" (by Avi Kapoor)
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields - Patterson Cos ( NASDAQ:PDCO ) , Gilead Sciences ( NASDAQ:GILD )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
In Article Trend: Neutral
April 25, 2024 (10:17) / "Benzinga" (by Shanthi Rexaline)
Meta, IBM Drag Nasdaq Futures Lower: What's Driving Premarket Action - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.'s META lukewarm second-quarter revenue guidance and commentary regarding investment punctured the stock, while International Business Machines Corp.
In Article Trend: Neutral
April 24, 2024 (13:19) / "Zacks Commentary" (by Ahan Chakraborty)
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
In Article Trend: Somewhat-Bullish
April 23, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Incyte ( INCY ) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 22, 2024 (17:57) / "Zacks Commentary" (by Zacks Equity Research)
Gilead ( GILD ) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
In Article Trend: Neutral
April 22, 2024 (13:16) / "Zacks Commentary" (by Zacks Equity Research)
Insights Into Gilead ( GILD ) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
In Article Trend: Neutral
April 21, 2024 (21:45) / "Benzinga" (by Shanthi Rexaline)
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
As the market runs into rough weather, the importance of the upcoming week's earnings cannot be emphasized enough. A lot is riding on the earnings reports of companies like Tesla, Inc. TSLA, Meta Platforms, Inc. META, Microsoft Corp. MSFT and Alphabet, Inc. GOOGL ( GOOG ) .
In Article Trend: Neutral
April 21, 2024 (10:18) / "Forbes" (by Bill Stone)
Better Earnings Don't Stop The Plunge In Stocks
The earnings season remained slow out of the gate, with only 41 S&P 500 companies reporting. Banks continued to be a large contingent of the reporters, which boosted the sector's earnings expectations for the quarter as most banks had better-than-expected earnings.
In Article Trend: Somewhat-Bullish
April 21, 2024 (05:34) / "Stocknews.com" (by Defense World Staff)
StockNews.com Lowers Gilead Sciences ( NASDAQ:GILD ) to Buy
Gilead Sciences ( NASDAQ:GILD - Get Free Report ) was downgraded by StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Friday. Other equities analysts also recently issued research reports about the stock.
In Article Trend: Somewhat-Bullish
April 19, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Increases Despite Market Slip: Here's What You Need to Know
Gilead Sciences (GILD) closed the most recent trading day at $66.76, moving +0.91% from the previous trading session.
In Article Trend: Neutral
April 19, 2024 (13:28) / "Benzinga" (by Vandana Singh)
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies - Johnson & Johnson ( NYSE:JNJ ) , Novartis ( NYSE:NVS ) , Gilead Sciences ( NASDAQ:GILD ) , Bristol-Myers Squibb ( NYSE:BMY )
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings-the highest safety-related caution for medications-for all chimeric antigen receptor ( CAR ) T-cell therapies.
In Article Trend: Neutral
April 18, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.
In Article Trend: Neutral
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 18, 2024 (17:16) / "Benzinga" (by Benzinga Insights)
What the Options Market Tells Us About Gilead Sciences - Gilead Sciences ( NASDAQ:GILD )
Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
April 18, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate Gilead Sciences ( GILD ) to Report a Decline in Earnings: What to Look Out for
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 17, 2024 (18:30) / "Benzinga" (by Benzinga Insights)
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences GILD has outperformed the market over the past 20 years by 3.77% on an annualized basis producing an average annual return of 11.45%. Currently, Gilead Sciences has a market capitalization of $83.93 billion.
In Article Trend: Somewhat-Bullish
April 17, 2024 (03:22) / "PR Newswire" (by Inc.)
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN ASIA
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ... PR ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (13:14) / "Zacks Commentary" (by Zacks Equity Research)
Xilio's ( XLO ) Shares Surge 79.8% in a Month: Here's Why
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
In Article Trend: Somewhat-Bullish
April 16, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences, Inc. ( GILD ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:00) / "Motley Fool" (by George Budwell)
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:00) / "Motley Fool" (by Jeremy Bowman)
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
Dividend stocks can be a smart way to ride out market volatility.
In Article Trend: Somewhat-Bullish
April 15, 2024 (05:06) / "PR Newswire" (by Inc.)
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ... PR ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (04:22) / "PR Newswire" (by Inc.)
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ... PR ...
In Article Trend: Somewhat-Bullish
April 12, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Stock Moves -0.84%: What You Should Know
In the most recent trading session, Gilead Sciences (GILD) closed at $68.07, indicating a -0.84% shift from the previous trading day.
In Article Trend: Neutral
April 11, 2024 (13:18) / "Business Insider" (by Avi Kapoor)
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
In Article Trend: Neutral
April 11, 2024 (12:46) / "Benzinga" (by Avi Kapoor)
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter - Gilead Sciences ( NASDAQ:GILD ) , UnitedHealth Group ( NYSE:UNH )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
In Article Trend: Neutral
April 11, 2024 (12:30) / "PR Newswire" (by Leap Therapeutics)
Leap Therapeutics Announces $40 Million Private Placement
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program
In Article Trend: Neutral
April 10, 2024 (11:00) / "GlobeNewswire" (by Nurix Therapeutics)
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Extended the Strategic Collaboration with Gilead Sciences ...
In Article Trend: Neutral
April 9, 2024 (22:15) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Gilead Sciences (GILD) closed at $69.94, indicating a +0.75% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
April 9, 2024 (18:40) / "Business Insider" (by Stavros Tousios)
3 Stocks at 52-Week Lows Poised for a Powerful Rebound
With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential.
In Article Trend: Somewhat-Bullish
April 8, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others.
In Article Trend: Somewhat-Bullish
April 8, 2024 (18:47) / "Benzinga" (by Surbhi Jain)
Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip? - Starbucks ( NASDAQ:SBUX ) , Gilead Sciences ( NASDAQ:GILD )
Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one such opportunity window. We looked at established companies that, recently, made new 52-week lows.
In Article Trend: Somewhat-Bullish
April 8, 2024 (17:27) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets FDA Nod for Label Expansion of Abecma
Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:23) / "PR Newswire" (by RedHill Biopharma Ltd.)
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base
In Article Trend: Neutral
April 6, 2024 (10:49) / "Motley Fool" (by David Jagielski)
3 No-Brainer Dividend Stocks to Buy in April
Income investors will find a lot to like about these stocks.
In Article Trend: Somewhat-Bullish
April 5, 2024 (12:30) / "Motley Fool" (by David Jagielski)
Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
All of these stocks pay generous dividends that income investors will appreciate.
In Article Trend: Somewhat-Bullish
April 3, 2024 (21:39) / "Benzinga" (by Globe Newswire)
Opthea Appoints Sujal Shah to the Board of Directors - Opthea ( NASDAQ:OPT )
MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 ( GLOBE NEWSWIRE ) -- Opthea Limited OPT the "Company" ) ) ) , a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration ...
In Article Trend: Somewhat-Bullish
April 3, 2024 (21:39) / "GlobeNewswire" (by Opthea Limited)
Opthea Appoints Sujal Shah to the Board of Directors
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair ...
In Article Trend: Somewhat-Bullish
April 3, 2024 (14:30) / "Benzinga" (by Benzinga Insights)
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences GILD has outperformed the market over the past 20 years by 4.41% on an annualized basis producing an average annual return of 12.26%. Currently, Gilead Sciences has a market capitalization of $90.11 billion.
In Article Trend: Somewhat-Bullish
April 3, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences, Inc. ( GILD ) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
April 2, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Dips More Than Broader Market: What You Should Know
Gilead Sciences (GILD) closed at $72.09 in the latest trading session, marking a -1.08% move from the prior day.
In Article Trend: Somewhat-Bullish
April 2, 2024 (20:05) / "Benzinga" (by Globe Newswire)
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer - Pulmonx ( NASDAQ:LUNG )
REDWOOD CITY, Calif., April 02, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation LUNG ( "Pulmonx" or the "Company" ) , a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024.
In Article Trend: Somewhat-Bullish
April 1, 2024 (18:37) / "Benzinga" (by Vandana Singh)
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress - Galapagos ( NASDAQ:GLPG )
Bank of America Securities downgrades European drugmaker Galapagos NV GLPG to underperform, citing few catalysts in the near term. Galapagos' enterprise value has been consistently low, ranging between $1.5 billion and $2 billion, and the analysts don't anticipate any immediate or medium-term ...
In Article Trend: Neutral
April 1, 2024 (12:08) / "Benzinga" (by Avi Kapoor)
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket - Doma Holdings ( NYSE:DOMA )
Shares of Doma Holdings Inc. DOMA rose sharply in today's pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading Here are some other stocks moving in pre-market trading.
In Article Trend: Neutral
March 28, 2024 (20:05) / "Benzinga" (by Globe Newswire)
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights - Assembly Biosciences ( NASDAQ:ASMB )
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366.
In Article Trend: Neutral
March 28, 2024 (18:56) / "Benzinga" (by Avi Kapoor)
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results - Avalo Therapeutics ( NASDAQ:AVTX ) , Biodexa Pharmaceuticals ( NASDAQ:BDRX )
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 15 points on Thursday. The Dow traded up 0.06% to 39,785.29 while the NASDAQ fell 0.13% to 16,383.85. The S&P 500 also rose, gaining, 0.10% to 5,253.70. Energy shares jumped by 1.1% on Thursday.
In Article Trend: Neutral
March 28, 2024 (16:39) / "Benzinga" (by Vandana Singh)
Why Is Cancer Focused Xilio Therapeutics Stock Trading Higher On Thursday? - Xilio Therapeutics ( NASDAQ:XLO ) , Gilead Sciences ( NASDAQ:GILD )
Xilio Therapeutics Inc XLO shares are surging as the company announced an exclusive license agreement with Gilead Sciences Inc GILD to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301.
In Article Trend: Somewhat-Bullish
March 28, 2024 (16:30) / "Benzinga" (by Avi Kapoor)
Gold Gains 1%; Walgreens Narrows Earnings Forecast - Avalo Therapeutics ( NASDAQ:AVTX ) , Biodexa Pharmaceuticals ( NASDAQ:BDRX )
U.S. stocks traded slightly higher midway through trading, with the S&P 500 gaining around 0.1% on Thursday. The Dow traded up 0.06% to 39,785.87 while the NASDAQ rose 0.06% to 16,408.04. The S&P 500 also rose, gaining, 0.13% to 5,255.09. Energy shares jumped by 0.6% on Thursday.
In Article Trend: Neutral
March 28, 2024 (14:32) / "Business Insider"
US Stocks Flat; Initial Jobless Claims Fall To 210,000
US Stocks Flat. Initial Jobless Claims Fall To ...
In Article Trend: Neutral
March 28, 2024 (14:32) / "Benzinga" (by Avi Kapoor)
US Stocks Flat; Initial Jobless Claims Fall To 210,000 - Avalo Therapeutics ( NASDAQ:AVTX ) , Biodexa Pharmaceuticals ( NASDAQ:BDRX )
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38.
In Article Trend: Neutral
March 28, 2024 (11:05) / "GlobeNewswire" (by Inc.)
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company's promising research platform for tumor-activated bispecific and cell ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (11:05) / "Benzinga" (by Globe Newswire)
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing - Xilio Therapeutics ( NASDAQ:XLO )
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company's promising research platform for tumor-activated bispecific and cell ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (12:13) / "Benzinga" (by Avi Kapoor)
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields - Johnson & Johnson ( NYSE:JNJ ) , Gilead Sciences ( NASDAQ:GILD )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
In Article Trend: Neutral
March 26, 2024 (06:38) / "Stocknews.com" (by Defense World Staff)
Gilead Sciences ( NASDAQ:GILD ) Lifted to "Strong-Buy" at StockNews.com
Gilead Sciences ( NASDAQ:GILD - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report released on Tuesday. Other research analysts have also issued research reports about the company.
In Article Trend: Somewhat-Bullish
March 25, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Stock Moves -0.04%: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $72.58, moving -0.04% from the previous trading session.
In Article Trend: Neutral
March 25, 2024 (11:00) / "Forbes" (by Dmitry Reykhart)
Council Post: What's Driving Big Pharma's Recent Market Performance?
What's Driving Big Pharma's Recent Market Performance? Forbes ...
In Article Trend: Neutral
March 22, 2024 (20:03) / "Investors Business Daily" (by ALLISON GATLIN)
Why This Top 1% Biotech Stock Just Plummeted 31%
Nkarta Stock Plummets After Biotech Deprioritizes Cancer Drug Investor's Business Daily ...
In Article Trend: Neutral
March 22, 2024 (14:44) / "Investors Business Daily" (by Investor's Business Daily)
Why This Top 1% Biotech Stock Just Plummeted 22%
Nkarta Stock Plummets After Biotech Scraps Cancer Drug For Lupus Treatment Investor's Business Daily ...
In Article Trend: Neutral
March 22, 2024 (11:01) / "GlobeNewswire" (by HOOKIPA Pharma Inc)
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
NEW YORK and VIENNA, Austria, March 22, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the fourth ...
In Article Trend: Neutral
March 21, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Axsome ( AXSM ) Down 4% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 21, 2024 (11:53) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets EC Nod for Abecma's Label Expansion
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.
In Article Trend: Somewhat-Bullish
March 20, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search Gilead Sciences, Inc. ( GILD ) : Here is What You Need to Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
March 19, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Rises But Trails Market: What Investors Should Know
Gilead Sciences (GILD) reachead $73.41 at the closing of the latest trading day, reflecting a +0.2% change compared to its last close.
In Article Trend: Somewhat-Bullish
March 19, 2024 (08:06) / "Stocknews.com" (by Defense World Staff)
Gilead Sciences ( NASDAQ:GILD ) Downgraded by StockNews.com to Buy
StockNews.com lowered shares of Gilead Sciences ( NASDAQ:GILD - Free Report ) from a strong-buy rating to a buy rating in a research report released on Monday morning. GILD has been the topic of a number of other reports.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:41) / "Benzinga" (by Globe Newswire)
Multiplex Assays Market on Track to Surpass USD 5.9 Billion by 2031 at a moderate CAGR of 6.9% | Analysis by Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 18, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global multiplex assays market is estimated to be valued at US$ 5.9 billion by 2031. As of 2022, the market valuation turned out to be US$ 3.2 billion.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:31) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers' ( BMY ) Abecma Gets ODAC Votes for Label Expansion
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
In Article Trend: Somewhat-Bullish
March 18, 2024 (09:36) / "PR Newswire"
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... PR ...
In Article Trend: Somewhat-Bullish
March 17, 2024 (12:15) / "Motley Fool" (by Prosper Junior Bakiny)
2 Top Dividend Stocks to Buy Hand Over Fist
Every company faces headwinds eventually. The top ones know how to bounce back.
In Article Trend: Somewhat-Bullish
March 15, 2024 (16:51) / "Benzinga" (by Vandana Singh)
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences Inc's GILD executive revealed the company's plans to increase its production of cell therapy cancer treatments fourfold by 2026. In an interview with Reuters, Cindy Perettie, the executive vice president of Gilead's Kite cell therapy unit, said the advancements stem from ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:14) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets FDA Nod for Breyanzi's Label Expansion
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
In Article Trend: Neutral
March 13, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Increases Despite Market Slip: Here's What You Need to Know
Gilead Sciences (GILD) closed the most recent trading day at $75.94, moving +1.15% from the previous trading session.
In Article Trend: Somewhat-Bullish
March 11, 2024 (21:30) / "Benzinga" (by Benzinga Insights)
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences GILD has outperformed the market over the past 20 years by 4.71% on an annualized basis producing an average annual return of 12.54%. Currently, Gilead Sciences has a market capitalization of $93.84 billion.
In Article Trend: Somewhat-Bullish
March 10, 2024 (10:35) / "Motley Fool" (by Keith Speights)
3 Dividend Stocks to Buy Hand Over Fist in March
Income investors might want to load up on these great dividend stocks.
In Article Trend: Somewhat-Bullish
March 9, 2024 (14:00) / "Motley Fool" (by Motley Fool Staff)
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
In Article Trend: Neutral
March 8, 2024 (15:02) / "Benzinga" (by Vandana Singh)
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer - BeiGene ( NASDAQ:BGNE )
Thursday, the FDA granted accelerated approval to BeiGene Ltd's BGNE Brukinsa ( zanubrutinib ) for adult patients with relapsed or refractory ( R/R ) follicular lymphoma ( FL ) , in combination with Roche Holdings AG's RHHBY Gazyva ( obinutuzumab ) , after two or more lines of systemic therapy.
In Article Trend: Somewhat-Bullish
March 7, 2024 (22:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Gilead Sciences ( GILD ) Outpaced the Stock Market Today
In the most recent trading session, Gilead Sciences (GILD) closed at $73.66, indicating a +1.42% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
March 7, 2024 (19:52) / "Benzinga" (by Vandana Singh)
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - Arcellx ( NASDAQ:ACLX )
Morgan Stanley initiates Arcellx Inc ACLX, noting a differentiated CAR-T platform for blood cancer backed by an established CAR-T partner. ddBCMA ( aka anito-cel ) is Arcellx's lead asset, incorporating its patent-protected D-domain as the extracellular binding domain.
In Article Trend: Somewhat-Bullish
March 7, 2024 (16:31) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Gilead ( GILD ) Down 2.4% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 7, 2024 (12:59) / "Zacks Commentary" (by Zacks Equity Research)
Gilead ( GILD ) & MRK's HIV Oral Combo Shows Efficacy in Phase II
Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.
In Article Trend: Neutral
March 6, 2024 (21:30) / "Benzinga" (by Vandana Singh)
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy - Merck & Co ( NYSE:MRK ) , Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences Inc GILD and Merck & Co Inc MRK released results from the Phase 2 clinical study evaluating the combination of islatravir and lenacapavir for HIV infection.
In Article Trend: Neutral
March 6, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Here is What to Know Beyond Why Gilead Sciences, Inc. ( GILD ) is a Trending Stock
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
March 4, 2024 (16:39) / "Benzinga" (by Vandana Singh)
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges - Gilead Sciences ( NASDAQ:GILD ) , GSK ( NYSE:GSK )
The Biden administration is working to preserve a crucial federal mandate compelling health insurers to cover preventive care services, including HIV-preventing medication and cancer screenings, without additional costs to patients. This mandate is integral to the 2010 Affordable Care Act ( ACA ) ...
In Article Trend: Neutral
March 4, 2024 (12:33) / "Forbes" (by Jamie Pfeiffer)
What Is The Expected Average Truvada Lawsuit Settlement?
Truvada was one of the first HIV drugs that was widely prescribed. It was effective in treating the virus, as well as preventing it when used as a pre-exposure prophylactic ( PrEP ) . However, it had some serious side effects, such as damaging the kidneys and causing loss of bone density.
In Article Trend: Somewhat-Bearish
March 1, 2024 (22:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Gilead Sciences ( GILD ) Gained But Lagged the Market Today
In the latest trading session, Gilead Sciences (GILD) closed at $72.31, marking a +0.29% move from the previous day.
In Article Trend: Somewhat-Bullish
February 29, 2024 (19:20) / "MarketWatch" (by Jeremy C. Owens)
Nvidia's next mission: Make even more financial history
No company has ever posted financial results quite like Nvidia's, but that just means Wall Street now expects the Silicon Valley chip maker to do something else that has never been done.
In Article Trend: Somewhat-Bullish
February 28, 2024 (21:45) / "GlobeNewswire" (by CymaBay Therapeutics)
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
In Article Trend: Somewhat-Bullish
February 28, 2024 (15:00) / "PR Newswire" (by IntegriChain)
Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board
PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Jim Meyers, a highly experienced pharmaceutical commercialization ...
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website